Drug Profile
Research programme: human heavy chain antibodies - Amgen
Alternative Names: UniAbs™; UniDabs™Latest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator TeneoBio
- Developer Amgen
- Class Anti-infectives; Antibodies; Antineoplastics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Infections; Lymphoma; Multiple myeloma; Prostate cancer